ARTICLE | Clinical News
Dapagliflozin meets diabetes endpoints
September 21, 2010 12:47 AM UTC
Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) said oral dapagliflozin as an add-on to glimepiride met the primary endpoint vs. placebo plus glimepiride in a Phase...